|
Benzimidazole 2
(internal name in literature) |
|
Vibrio |
Post-translational modification |
Preclinical (in vitro) |
Wang G, et al. 2022. ChemMedChem |
|
Compound 7
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
Compound 13
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
| (E)-3-(4-fluorophenyl)-N-[4-(1-hydroxy-5-methyl-6-nitrobenzimidazol-2-yl)phenyl]prop-2-enamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kim OK, et al. 2009. J Med Chem |
|
| (E)-N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]-3-(4-methoxyphenyl)prop-2-enamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kim OK, et al. 2009. J Med Chem |
|
| 1,3-dioxo-2-[4-(4-phenylquinazolin-2-yl)phenyl]-2,3-dihydro-1H-isoindole-5-carboxylic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Eriksson J, et al. 2012. Adv Exp Med Biol |
|
| 1,6-dimethyl-3-(thiophen-2-yl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 1-[(5Z)-5-(1-butyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]piperidine-4-carboxamide |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 2,6-bis[4-(4-aminophenyl)sulfonylphenyl]pyrrolo[3,4-f]isoindole-1,3,5,7-tetrone |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Eriksson J, et al. 2012. Adv Exp Med Biol |
|
| 2,8-bis(5-methyl-2-furyl)pyrido[3,2-g]quinoline-4,6-dicarboxylic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Eriksson J, et al. 2012. Adv Exp Med Biol |
|
| | | |
